Chronic Lymphocytic Leukemia Podcasts This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Venetoclax combination therapy for relapsed CLL
While single agents are able to control relapsed chronic lymphocytic leukemia (CLL) well, they do not provide a cure. In this interview, Anna Schuh, MD, PhD, from the University of Oxford, Oxford, UK,... Author: VJHemOnc Added: 01/30/2018 (Source: Oncology Tube)
Source: Oncology Tube - January 30, 2018 Category: Cancer & Oncology Source Type: podcasts

Small molecule inhibitors for CLL: which to use, sequencing, switching and combinations
There are now three small molecule inhibitors to choose from for the treatment of chronic lymphocytic leukemia (CLL): Ibrutinib, idelalisib and venetoclax. In this video, Susan OBrien, MD, of the Uni... Author: VJHemOnc Added: 01/17/2018 (Source: Oncology Tube)
Source: Oncology Tube - January 17, 2018 Category: Cancer & Oncology Source Type: podcasts

Novel BTK inhibitor acalabrutinib shows promise in CLL
A novel BTK inhibitor, acalabrutinib, is showing promise in the early clinical trial stages for chronic lymphocytic leukemia (CLL). Speaking from the American Society of Hematology (ASH) 2017 Annual M... Author: VJHemOnc Added: 01/17/2018 (Source: Oncology Tube)
Source: Oncology Tube - January 17, 2018 Category: Cancer & Oncology Source Type: podcasts

Small molecule inhibitors for CLL: which to use, sequencing, switching and combinations
There are now three small molecule inhibitors to choose from for the treatment of chronic lymphocytic leukemia (CLL): Ibrutinib, idelalisib and venetoclax. In this video, Susan OBrien, MD, of the Uni... Author: VJOncology Added: 01/16/2018 (Source: Oncology Tube)
Source: Oncology Tube - January 16, 2018 Category: Cancer & Oncology Source Type: podcasts

Novel BTK inhibitor acalabrutinib shows promise in CLL
A novel BTK inhibitor, acalabrutinib, is showing promise in the early clinical trial stages for chronic lymphocytic leukemia (CLL). Speaking from the American Society of Hematology (ASH) 2017 Annual M... Author: VJOncology Added: 01/16/2018 (Source: Oncology Tube)
Source: Oncology Tube - January 16, 2018 Category: Cancer & Oncology Source Type: podcasts

How do we sequence and combine novel agent-based therapies in CLL?
There are now many drugs available for the treatment of chronic lymphocytic leukemia (CLL); however, there is only limited data regarding the best order and combination to administer them in. Here, Ma... Author: VJHemOnc Added: 01/11/2018 (Source: Oncology Tube)
Source: Oncology Tube - January 11, 2018 Category: Cancer & Oncology Source Type: podcasts

Determining the best course of treatment for younger patients with relapsed/refractory CLL
The optimal treatment for younger patients with relapsed/refractory chronic lymphocytic leukemia (CLL) depends on a number of factors, including what was given as the frontline treatment. Speaking fro... Author: VJHemOnc Added: 01/11/2018 (Source: Oncology Tube)
Source: Oncology Tube - January 11, 2018 Category: Cancer & Oncology Source Type: podcasts

Exciting results for frontline ibrutinib plus FCR for younger CLL patients
There are now many effective therapies to choose from for chronic lymphocytic leukemia (CLL). Thus, a recent area of therapeutic development in CLL is the creation of time-limited regimens and curativ... Author: VJHemOnc Added: 01/11/2018 (Source: Oncology Tube)
Source: Oncology Tube - January 11, 2018 Category: Cancer & Oncology Source Type: podcasts

Strategies for treating Richters transformation in CLL: checkpoint inhibitors and venetoclax
Richters transformation remains a challenge in chronic lymphocytic leukemia (CLL). In this interview, Matthew Davids, MD, of the Dana-Farber Cancer Institute, Boston, MA, discusses the key approaches... Author: VJHemOnc Added: 01/11/2018 (Source: Oncology Tube)
Source: Oncology Tube - January 11, 2018 Category: Cancer & Oncology Source Type: podcasts

Ibrutinib and FCR chemoimmunotherapy: improving complete remission in CLL patients?
Recent data have suggested that chronic lymphocytic leukemia (CLL) patients, in particular those with mutated immunoglobulin heavy chain genes, can have prolonged responses to FCR chemoimmunotherapy. ... Author: VJHemOnc Added: 01/09/2018 (Source: Oncology Tube)
Source: Oncology Tube - January 9, 2018 Category: Cancer & Oncology Source Type: podcasts

CLL updates from ASH 2017
A range of chronic lymphocytic leukemia (CLL) research was presented at the American Society of Hematology (ASH) 2017 Annual Meeting and Exposition in Atlanta, GA. Speaking from the meeting, Dr Barrie... Author: VJHemOnc Added: 01/08/2018 (Source: Oncology Tube)
Source: Oncology Tube - January 8, 2018 Category: Cancer & Oncology Source Type: podcasts

Ibrutinib combination regimens for CLL from ASH 2017
Despite the combination of ibrutinib and rituximab not significantly affecting progression-free survival in patients with chronic lymphocytic leukemia (CLL), many groups are testing ibrutinib combinat... Author: VJHemOnc Added: 01/08/2018 (Source: Oncology Tube)
Source: Oncology Tube - January 8, 2018 Category: Cancer & Oncology Source Type: podcasts

Are newer, targeted agents better for the managment of untreated CLL than chemoimmunotherapy?
The targeted agent ibrutinib has been tested as a first-line monotherapy in elderly chronic lymphocytic leukemia (CLL) in the RESONATE-2 trial (NCT01722487); however, within CLL, it has not been teste... Author: VJHemOnc Added: 01/08/2018 (Source: Oncology Tube)
Source: Oncology Tube - January 8, 2018 Category: Cancer & Oncology Source Type: podcasts

Are newer, targeted agents better for the management of untreated CLL than chemoimmunotherapy?
The targeted agent ibrutinib has been tested as a first-line monotherapy in elderly chronic lymphocytic leukemia (CLL) in the RESONATE-2 trial (NCT01722487); however, within CLL, it has not been teste... Author: VJHemOnc Added: 01/08/2018 (Source: Oncology Tube)
Source: Oncology Tube - January 8, 2018 Category: Cancer & Oncology Source Type: podcasts

Novel venetoclax combination therapy advancing the field of CLL
In chronic lymphocytic leukemia (CLL), venetoclax has established itself as one of the most effective monotherapies in certain contexts. Speaking from the American Society of Hematology (ASH) 2017 Ann... Author: VJHemOnc Added: 12/15/2017 (Source: Oncology Tube)
Source: Oncology Tube - December 15, 2017 Category: Cancer & Oncology Source Type: podcasts